

RESEARCH ARTICLE

Open Access

Role of tight junction proteins in gastroesophageal reflux disease

Klaus Mönkemüller^{1,2†}, Thomas Wex^{1*†}, Doerthe Kuester³, Lucia C Fry^{1,2}, Arne Kandulski¹, Siegfried Kropf⁴, Albert Roessner³ and Peter Malfertheiner¹**Abstract**

Background: Gastroesophageal reflux disease (GERD) is associated with impaired epithelial barrier function that is regulated by cell-cell contacts. The aim of the study was to investigate the expression pattern of selected components involved in the formation of tight junctions in relation to GERD.

Methods: Eighty-four patients with GERD-related symptoms with endoscopic signs (erosive: $n = 47$) or without them (non-erosive: $n = 37$) as well as 26 patients lacking GERD-specific symptoms as controls were included. Endoscopic and histological characterization of esophagitis was performed according to the Los Angeles and adapted Ismeil-Beigi criteria, respectively. Mucosal biopsies from distal esophagus were taken for analysis by histopathology, immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (RT-PCR) of five genes encoding tight junction components [Occludin, Claudin-1, -2, Zona occludens (ZO-1, -2)].

Results: Histopathology confirmed GERD-specific alterations as dilated intercellular spaces in the esophageal mucosa of patients with GERD compared to controls ($P < 0.05$). Claudin-1 and -2 were 2- to 6-fold upregulation on transcript ($P < 0.01$) and in part on protein level ($P < 0.015$) in GERD, while subgroup analysis of revealed this upregulation for ERD only. In both erosive and non-erosive reflux disease, expression levels of Occludin and ZO-1,-2 were not significantly affected. Notably, the induced expression of both claudins did not correlate with histopathological parameters (basal cell hyperplasia, dilated intercellular spaces) in patients with GERD.

Conclusions: Taken together, the missing correlation between the expression of tight junction-related components and histomorphological GERD-specific alterations does not support a major role of the five proteins studied in the pathogenesis of GERD.

Keywords: Gastroesophageal reflux disease, Tight junction, Claudins, Esophagitis, Inflammation

Background

Gastroesophageal reflux disease (GERD) is one of the most prevalent gastrointestinal disorders in the world [1,2]. Based on endoscopic findings GERD is differentiated in erosive (erosive reflux disease or ERD), non-erosive reflux disease (NERD) and Barrett's esophagus (BE) [3,4]. ERD is characterized by endoscopic visible breaks of esophageal mucosa integrity and classified according to various endoscopic classifications, most recently the Los Angeles classification [5,6]. However,

two thirds of patients with typical GERD symptoms do not exhibit visible mucosal changes in conventional esophagogastroduodenoscopy (EGD) and are thus diagnosed as having NERD [6,7]. Although histology is not used in clinical practice for GERD diagnosis, frequent histological changes as basal cell hyperplasia, elongation of the papilla, inflammatory infiltrates and dilatation of the intercellular spaces are observed in the distal esophagus of patients with both ERD and NERD [8-11]. Dilations of the intercellular spaces (ICS) are characteristic changes of the esophageal mucosa of patients with ERD and NERD. ICS were described by various others using electron microscopy and are even characterized by light microscopy. This feature is being more widely proposed as an additional morphological feature of acid-

* Correspondence: thomas.wex@med.ovgu.de

†Equal contributors

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Leipziger Str. 44, Magdeburg 39120, Germany

Full list of author information is available at the end of the article

induced damage to the squamous epithelium [10,12-14]. The widened ICS are supposed to permit the diffusion of molecules to the lamina propria where sensory nerve endings are located [15]. Therefore, ICS dilation even in the absence of endoscopically visible mucosal damage may explain the occurrence of symptoms in patients with NERD [16,17]. Furthermore, recent studies have provided evidence that the impaired barrier function of esophageal mucosa is a “hallmark” of GERD [18-20]. The integrity of epithelial surfaces is based on various cell-cell contacts that provide the structural basis for barrier function by regulating the diffusion of molecules and sorting of transmembrane proteins to apical and basolateral surfaces. Tight junctions, adherens junction and desmosomes are the three major structural units mediating barrier and sorting function [21,22]. Their structural composition, general functions, and pathophysiological relevance have been reviewed extensively by others [21,23,24]. In line with the current concept in GERD, the role of molecules contributing to cell-cell contacts in esophageal mucosa in relation to GERD has been investigated in animal and human studies recently. Notably, the majority of studies were focused on the role of tight junction molecules (e.g. Claudin-2, -3, -4, -7 and -18) in Barrett’s metaplasia and carcinogenesis towards esophageal adenocarcinoma [25-30]. In regard to the other 2 endoscopic entities (ERD, NERD), distinct alterations in the expression and or localization were described for Claudins 3 and 4 in GERD-related animal and *in vitro* models [31-33]. Rat model revealed decreased expression of Claudin-3 and no change of Claudin-1 and 4 [31,32], while an *in vitro* model of esophageal-like squamous cells demonstrated a prominent role of Claudin-4 [33].

Here, we studied the expression patterns of five tight-junction related molecules (Occludin, Claudin-1, -2 and Zonula occludens-1, 2) in the esophageal mucosa of a prospective cohort of patients with GERD as well as reflux-negative individuals. Gene expression was assessed both on transcriptional and protein level, and changes were studied in context to histopathological alterations associated with GERD.

Methods

Study design and patients’ characteristics

Between 2005 and 2007, a cohort of patients with GERD and individuals lacking any symptom or endoscopic sign of GERD as GERD-negative controls were enrolled [34]. Patients with typical GERD-related symptoms based on Montreal classification [4] and patients without any reflux-related clinical symptoms undergoing EGD for screening or non-reflux dyspepsia (GERD-negative controls with a reflux disease questionnaire, RDQ score of 0) were invited to participate. All the patients underwent

a detailed history and physical examination. The demographic data and endoscopic findings of the study population are presented in Table 1A and Table 1B. Written informed consent was obtained from all patients before endoscopy, after the endoscopist had explained the procedure to the patient in detail and answered all questions. The study was approved by the ethical committee of our institution and conducted according to the ethical guidelines of the declaration of Helsinki as revised in 1989.

Functional investigations such as 24 hour-pH-metry or MII-pH analysis were performed in individual cases only, and could not be included as separate parameter. The assignment of NERD was additionally based on the responsiveness to PPI therapy that was subsequently assessed.

Inclusion criteria

Female or male, age 18 to 80, able to provide written informed consent. Patients with typical reflux symptoms had to present symptoms at least three times a week. Typical reflux symptoms were defined as heartburn and regurgitation, as evaluated by the RDQ score. Patients with other types of reflux symptoms were not included in this study.

Exclusion criteria

Upper gastrointestinal pathology (e.g. peptic ulcers, cancers, polyps, and Barrett’s mucosa), systemic inflammatory, neoplastic or malabsorptive diseases (e.g. Crohn’s disease, ulcerative colitis, vasculitis, celiac disease), and acute medical conditions such as pneumonia, stroke, coronary ischemia and acute renal failure. Patients with known abnormal coagulation parameters and thrombocytopenia at the time of the procedure (i.e. INR > 1.2, platelet count < 80,000) were also excluded. None of the patients had taken antibiotics, or bismuth compounds or any H₂-blockers or proton-pump inhibitors (PPI) in the last 2 weeks before entering the study. It is notable that the majority of patients enrolled had various anti-secretory medications in their past, and does not present GERD-naïve patients. Each patient was assigned a coded number. Histopathological assessment was done by pathologist (DK) blinded to clinical data.

Endoscopy and histopathology

The patients underwent the procedure after an overnight fast. The endoscopy was performed under conscious sedation with intravenous midazolam using a video-gastroscope (Q160, Olympus, Hamburg). Endoscopic characterization of esophagitis was performed according to the “Los Angeles classification” [35] describing the following endoscopic landmarks: gastroesophageal junction (GEJ), Z-line, beginning of the gastric folds and

Table 1 Patient groups analyzed by quantitative RT-PCR and immunohistochemistry

Quantitative RT-PCR	Controls (n = 26)	NERD (n = 37)	ERD (n = 47)
Sex (male/female)	6/20	6/31	31/16 [#]
Age (mean, sd, range)	52.3 ± 17.6 (20–79)	47.0 ± 14.1 (18–72)	47.5 ± 15.4 (20–79)
<i>H. pylori</i> -status (positive)	5/21 (23.1 %)	7/30 (22 %)	12/35 (29.2 %)
Immunohistochemistry	Controls (n = 12)	NERD (n = 13)	ERD (n = 16)
Sex (male/female)	2/10	4/9	10/6 [#]
Age (mean, sd, range)	46.2 ± 19.1 (20–75)	48.9 ± 9.5 (35–64)	48.6 ± 14.1 (29–72)
<i>H. pylori</i> -status (positive)	4/8 (33.3 %)	2/11 (15.4 %)	7/9 (43.8 %)

diaphragmatic pinch. The GEJ was defined as the beginning of the gastric folds, whereas the Z-line was defined as the squamocolumnar junction. The cardia was defined as the mucosa lying immediately below the GEJ.

In the distal esophagus, 3 biopsies were taken 2 cm above the squamous-columnar junction at the 3 o'clock position. In case of erosions, specimens were taken 2 cm above the tip of the erosion. One biopsy was snap-frozen in liquid nitrogen for molecular analysis. The two other biopsies were immediately fixed in 4 % neutral-buffered formalin and submitted for histopathological examinations using hematoxylin and eosin, modified Giemsa and PAS stain. In analogy to the Sydney classification for gastritis, the density of intraepithelial neutrophils/eosinophils and lymphocytes were scored to evaluation active and chronic inflammation. Furthermore, degree of basal cell hyperplasia, presence of papillary elongation and dilated intercellular spaces were semiquantitatively scored as either 0 (absent), 1 (mild), 2 (moderate), or 3 (severe) as described previously [34]. Notably, several subgroups of the study cohort were published in regard to inflammatory mediators (e.g. cytokines, Protease-activated receptor 2) [34,36], molecules related to barrier functions [37,38], desmosomal proteins [39] and histopathological alterations [34].

Extraction of RNA and quantitative reverse transcription - polymerase chain reaction (RT-PCR) analysis of tight junction-related genes

Extraction of total RNA and cDNA synthesis were performed by the “two-step” protocol as described previously [40]. Transcript levels of Occludin, Claudin-1, -2, Zonula occludens-1, -2, and β -Actin were determined by quantitative real-time RT-PCR using an iCycler (BioRad, Munich, Germany) and the QuantiTect™ SYBR Green kit (Qiagen) using primers and standard conditions described in Table 2. Initial template mRNA amounts for all genes were calculated using iCycler software (Ct-

values) and serial dilutions of plasmid DNA standard containing the corresponding PCR-fragments. Calculating template concentrations based on the Ct method and standard dilutions allowed an individual assessment of different efficiency for each PCR assay that were between 0.95 and 0.99. Gene-specific levels were normalized to the corresponding β -actin level of the sample. Final results are expressed as arbitrary units (a.u.) and represent ratios between investigated gene and β -Actin transcript amounts. All together, gene expression levels are identical to those calculated by the $2^{-\Delta\Delta Ct}$ -method [41], but they are additionally adjusted to the assay-specific efficiency. Due to the primer design (usage of intron-spanning regions), amplification of genomic DNA was excluded. All amplification products were checked for their correct size by agarose gel electrophoresis. Therefore, gene expression levels (a.u.) illustrate the mRNA pool of the individual gene studied.

Immunohistochemical analysis of tight junctional components

Immunohistochemistry was performed using the avidin-biotin complex immunostaining method and the automated immunohistochemistry slide staining system by Ventana NexES (Ventana Medical System, Strasbourg, France) as described previously [36]. Details for antigen retrieval and primary antibodies are illustrated in Table 2. Dilutions of primary antibodies were determined using appropriate positive and negative controls. For negative controls, primary antibody was replaced by irrelevant rabbit IgG that did not reveal specific signals (data not shown). Immunoreactivity was assessed in 5 representative high power fields (Zeiss Axioskop 50) of each sample by one blinded pathologist (DK). For semiquantitative assessment an adaptation of a score system originally described by Remmele et al. was applied [42]. Briefly, staining intensity ([SI], 1 = weak, 2 = moderate, 3 = strong) and the percentage of positive cells ([PPC], 1 = <10%,

Table 2 Characteristics of primers, RT-PCR protocol and antibodies

	Primer sequence, length of fragment, annealing temperature	Antibody, Company, Antigen retrieval, final dilution
Occludin	fw: GGCCATTGCCATTGTACTGGG rv: GGAACCGGCGTGGATTATAGG315 bp; 58°C	polyclonal rabbit anti-occludin antibody No. 71-1500 (Invitrogen, Carlsbad, CA, USA), Protease-retrieval, Final dilution: 1:50
Claudin-1	fw: ATGGTGGTTGGCATCCTCTG rv: GGCCTTGGTGGGTAAGAGG344 bp, 58°C	polyclonal rabbit anti-Claudin-1 antibody No. 51-9000, clone JAY.8 (Invitrogen, Carlsbad, CA, USA), EDTA-retrieval, Final dilution: 1:50
Claudin-2	fw: TCTCTGGCCTCCAACCTGTGGG rv: GCACTGGATGTCACCATCATGGC259 bp, 60°C	polyclonal rabbit anti-Claudin-2 antibody No. 51-6100 (Invitrogen, Carlsbad, CA, USA), EDTA-retrieval, Final dilution: 1:50
ZO-1	fw: TCTGATCATCCAGGCACTCGC rv: CCACATCTGGTTGCCAATTGG225 bp, 58°C	polyclonal rabbit anti-ZO-1 antibody No. 61-7300, (Invitrogen, Carlsbad, CA, USA), Protease retrieval, Final dilution: 1:30
ZO-2	fw: AGAGGACACGCCGAGCAGATTG rv: TCCCGACATCATGGCCACAG272 bp, 60°C	polyclonal rabbit anti-ZO-2 antibody No. 71-1400, (Invitrogen, Carlsbad, CA, USA), EDTA retrieval, Final dilution: 1:150
β-Actin	fw: CATGCCATCTGCGTCTGGACC rv: ACATGGTGGTGCCGCCAGACAG400 bp, 60°C	not performed
Standard protocol	95°C: 15 min; (94°C: 30s, 58°-60°C: 30s, 72°C: 30s) 40 cycles; 72°C: 5 min	

mab: monoclonal antibody, fw: forward, rv: reverse.

2 = 10-50%, 3 = 51-80%, 4 = > 80%) were scored semi-quantitatively, resulting in an immunoreactive score [IRS = SI × PC] between 0 and 12. Furthermore, a score for membranous staining (0 = none, 1 = weak, 2 = moderate, 3 = strong/complete) was added resulting in a possible maximum of 15 points for each sample.

Statistical analysis

Data are expressed as absolute number, relative proportion, median + range or mean ± standard deviation (SD) if not stated otherwise. Since the majority of data sets revealed skewed distribution, non-parametric Kruskal-Wallis test were applied for all comparisons made among the three groups (controls, NERD and ERD). If significant differences were identified ($P < 0.05$), post hoc analyses for pairwise comparisons between groups were performed using Mann-Whitney U test for gene expression analysis and immunohistochemistry. Age and histopathological parameters were analyzed by ANOVA and T test; frequencies by chi-square test. Non-parametric correlation analysis was performed by Spearman's rank correlation test to investigate potential association between gene expression levels and histomorphological changes. Correlation analyses were performed in explorative manner only; adjustment for multiple comparisons was not performed. All tests were applied two-sided with a level of significance of $P < 0.05$.

Results

Patients and GERD-specific histomorphological changes

The three groups as well as the subgroups (randomly selected for immunohistochemistry) did not differ with respect to age and *H. pylori* status (Table 1). Histomorphological alterations are shown in Table 3. Activity and chronicity scores in esophageal mucosa were slightly higher in patients with NERD or ERD vs. controls

without reaching significance. Basal cell hyperplasia, dilated intercellular spaces and elongation of papilla were significantly increased in both endoscopic entities (Table 3).

Upregulation of tight junction-related proteins in esophageal mucosa in context to the presence of gastroesophageal reflux disease

As exemplarily demonstrated in figure 1, Claudin-1 transcript and protein levels in esophageal mucosa were significantly increased in patients with ERD, while a weaker increase was noted in NERD compared to controls. Corresponding data for the other four genes (Claudin-2, ZO-1, ZO-2; Occludin) including those of Claudin-1 are summarized in tables 4A and 4B. Claudin-2 had a similar expression pattern as Claudin-1, and both ZO-1 and ZO-2 showed a tendency to higher transcript levels in ERD and NERD (P -values < 0.07 , Table 4A). In addition to the upregulation in context to controls, both transcript levels and immunohistochemical scores of Claudin-1 were significantly higher in patients with ERD compared to those with NERD (Figure 1).

In general, higher transcript levels were accompanied by higher immunohistochemical scores for most proteins. In addition to these quantitative changes in gene expression, different patterns of protein distribution within the cell compartment and within different mucosal layers were noted (Figure 2). In controls, the expression of tight junction-related proteins was mainly observed in the basal epithelial layers and in a cytoplasmic pattern. In GERD, expansion of protein expression to the suprabasal und spinous epithelial layers was observed. Furthermore, expression of Claudin-1, Claudin-2 and ZO-1 was partly membrane-associated with a stronger intensity in GERD compared to controls.

Table 3 Histopathological parameters

	Controls	NERD	ERD	P-value One way ANOVA
Activity	0 ± 0	0.23 ± 0.54	0.22 ± 0.41	n.s.
Chronicity	0.72 ± 0.54	0.97 ± 0.51	1.05 ± 0.67	n.s.
Basal cell hyperplasia [BSH]	0.52 ± 0.59	1.11 ± 0.63	1.42 ± 0.84	<0.001
Papillary elongation [PE]	1.32 ± 0.80	1.71 ± 0.86	2.07 ± 0.85	<0.001
Dilated intercellular spaces [ICS]	0.72 ± 0.68	1.49 ± 1.01	2.10 ± 0.13	<0.001

Parameters were scored semiquantitatively as described in "Patients and Methods". Data are presented as mean ± sd.

Increased gene expression of tight junction-related molecules (transcript level) does not correlate with histomorphological changes in esophageal mucosa

In order to study potential correlations between gene expression levels (transcript level) and the degree of histopathological alterations, all three groups were analyzed together in the first step. As exemplarily illustrated in figure 3, gene expression levels of Claudin-1 and Claudin-2 marginally correlated with the degree of basal cell hyperplasia, but not with dilated intercellular spaces and length of papilla (data not shown). Since most analyses were negative, these data are summarized in Table 5A for all five genes. Since basal cell hyperplasia revealed some even weak correlations in the complete study cohort, these correlation analyses were performed again for all three groups individually and for patients with GERD (NERD + ERD) combined. Only 3 out of 20 subanalyses revealed marginally significant correlations (without adjustment for multiple comparisons), two of those were identified in controls (data summarized in Table 5B).

In addition to the correlation based on transcript levels (Figure 3, Table 5), correlation analysis between protein expression levels (immunohistochemical scores, Table 4B) and histopathological alterations (Table 3) was performed. Here, only one significant correlation (between Claudin-1 and activity of inflammation, $r = 0.51$, $P < 0.01$) was identified (data not shown).

Discussion


In this study, we demonstrated (I) distinct expression patterns of five genes encoding for proteins involved in the formation of tight junctions in esophageal mucosa. In particular Claudin-1 in ERD and to lesser extent Claudin-2 was expressed at higher levels in patients with GERD. In contrast, ZO-1, ZO-2, and Occludin were not affected by the presence of GERD. (II) In general, altered gene expression of Claudin-1/-2 did not correlate with the degree of histomorphological changes in the esophageal mucosa of patients with GERD.

Tight junctions are composed of transmembrane proteins such as Occludin, 24 Claudins, several junctional adhesion molecules (JAMs) with different isoforms, E-

Cadherin as well as cytosolic binding partners [43,44]. The selection of the five genes studied was based on functional aspects. Occludin is critical for the formation of tight junctions in most tissues [45]. Claudin-1 is one of the numerous Claudins that seals intercellular space leading to higher barrier function [46], while Claudin-2 is the only pore-forming member of this family resulting in increased permeability [47]. Zonula occludens (ZO)-1 and -2 are cytosolic partners of tight junctions in most epithelial surfaces [48,49]. The selected genes present important components of the tight junctional complex, and were considered to allow assessment about alterations of tight junctions in relation to GERD. A comprehensive analysis concerning the general expression pattern of other junctional proteins was not performed.

Recently, several studies demonstrated characteristic histopathological alterations in esophageal mucosa of patients with GERD and a proinflammatory response including the activation of related pathways such as NFκB, PAR-2, ROS and iNOS [50,51]. Several *in vitro* and animal studies have provided evidence that incubation of esophageal mucosa or squamous cell lines either with acidified media with/without bile acids or proinflammatory cytokines can provoke changes in transepithelial electric resistance and increased transepithelial permeability [52-55]. Notably, several studies demonstrated a cytokine-mediated change of tight junction-related molecules in various cell models. For instance, IL-6 markedly induces Claudin-2 expression *via* MEK and PI3K signaling leading to increased tight junction permeability [56]. In a rabbit model of GERD, elevated IL-6 expression correlated with induction of several tight junction-related proteins (Claudin-1, Occludin, JAM-1, ZO-1) [57] and altered the motogenic activity of smooth muscle cells [58].

All together, there is sufficient data showing that the exposure of mixed gastric or gastroduodenal refluxate causes altered esophageal epithelial barrier function, inflammation and cellular damage, although the timely order of these processes is a matter of debate [20]. As today, it is well accepted that impaired epithelial barrier function of the distal esophagus presents a major pathophysiological process in GERD.



This study shows an upregulation of tight junction-related proteins in relation to ERD and NERD in mucosal samples. In particular, Claudin-1 and Claudin-2, though mediating opposite functionally effects, were induced, while cytoplasmic adapters and Occludin were rather unchanged in relation to controls. The higher

expression of Claudin-1 (both on transcript and protein level) was the only significant difference identified between patients with ERD and NERD. The fact that all other identified changes were similar between NERD and ERD supports the concept of similar pathophysiological mechanisms between both diseases. Unexpectedly, these changes did not correlate with histomorphological alterations, in particular with dilated ICS in esophageal mucosa. This finding is in contrast to the recently identified correlation between histopathological alterations, in particular basal cell hyperplasia, and elevated gene expression of desmosomal proteins [39]. In this study, few borderline correlations were found for basal cell hyperplasia and some genes only, but notably these findings were mostly restricted to reflux-negative controls, whereas patients with GERD did not reveal significant correlations between histopathological alterations and transcript levels of the five genes. Since correlation analyses were performed in an explorative way (without adjustment for multiple comparison), the few significant correlations (with borderline significance) do not support a general role of these findings for the pathophysiology of GERD. Taken into consideration this limitation and the fact that the overall majority of our comparisons (17 out of 20) revealed no correlations, we conclude that our data do not give evidence for an association between the gene expression of the five genes studied and the histopathological changes in our study groups. It is well known that extent of basal cell hyperplasia reflects proliferative status of esophageal mucosa [9]. Since the identified correlations between gene expression levels and basal cell hyperplasia were mostly restricted to controls, it is unlikely that elevated Claudin-1 levels in ERD reflect tissue repair in context to mucosal damage caused by refluxate in these patients. Since we and others demonstrated more severe histomorphological alterations in ERD than NERD, the overall consistent changes of the 5 genes and their corresponding proteins in both diseases seem to be of limited relevance to the mucosal integrity and function. Furthermore, it is notable that some of the stainings revealed not the typical membrane-restricted expression pattern as demonstrated for these tight junction-related molecules in most gastrointestinal tissues [59,60]. However, cytoplasmic or diffuse membranous expression patterns have been identified for Claudin-2 [60] and ZO-1 [61] in human gastrointestinal tissue and for Claudin-1 in esophageal mucosa of rat [62]. Occludin staining pattern or expression in esophageal mucosa differs frequently also from those identified in gastric or intestinal mucosa [60,63]. Overall, the subcellular distribution of the 5 tight junction-related proteins seems to differ partially from those identified in columnar-lined epithelium. However, the study was

Table 4 Expression of tight junction-related components in esophageal mucosa in patients with GERD

Panel A Transcript level	Gene expression/ β -actin (a.u.) median (range)	Change vs. controls (x-fold)	P-values (* Kruskal-Wallis; posthoc: Man Whitney U test)
Occludin			<i>0.098*</i>
controls	0.041 (0.0086 - 0.38)		
NERD	0.060 (0.0052 - 0.57)	1.46	n.a.
ERD	0.035 (0.0026 - 1.09)	0.85	n.a.
Claudin-1			0.0097*
controls	0.078 (0.0072 - 2.54)		
NERD	0.15 (0.012 - 1.6)	1.92	0.016
ERD	0.20 (0–4.1)	2.56	0.0032
Claudin-2			0.0027*
controls	0.000038 (0–0.003)		
NERD	0.0002 (0–0.019)	5.26	0.0041
ERD	0.000083 (0–0.021)	2.18	0.11
ZO-1			<i>0.069*</i>
controls	0.0060 (0.0012 - 0.073)		
NERD	0.0081 (0–0.067)	1.35	n.a.
ERD	0.0077 (0.0015 - 0.21)	1.28	n.a.
ZO-2			<i>0.061*</i>
controls	0.011 (0.0022 - 0.038)		
NERD	0.019 (0.002 - 0.27)	1.72	n.a.
ERD	0.021 (0.0019 - 0.59)	1.9	n.a.
Panel B Protein level	IHC score median (range)	Change (x-fold) vs. controls	P-values (* Kruskal-Wallis; posthoc: Man Whitney U test)
Occludin			0.02*
controls	3 (1 – 9)		-
NERD	6 (1 – 15)	2.0	0.026
ERD	8 (1 – 12)	2.7	0.012
Claudin-1			0.014*
controls	1 (1 – 4)		-
NERD	2 (1 – 9)	2.0	0.14
ERD	6 (1 – 8)	6.0	0.0004
Claudin-2			0.0057*
controls	4 (1 – 9)		-
NERD	6 (1 – 12)	1.5	0.28
ERD	9 (4 – 15)	2.25	0.0025
ZO-1			<i>0.62*</i>
controls	2 (0 – 6)		-
NERD	4 (1 – 12)	2.0	n.a.
ERD	3 (0 – 3)	1.5	n.a.
ZO-2			<i>0.58*</i>
controls	4 (0 – 10)		-
NERD	4 (0 – 8)	1.0	n.a.
ERD	1 (0 – 8)	0.25	n.a.

Transcript levels are shown in relation to controls (Panel A). Immunohistochemical scores are illustrated similarly (Panel B). Statistical analyses for both datasets were done first by non-parametric Kruskal-Wallis (*P-value italic style*); if significant post-hoc analysis was done by Mann Whitney U test. Significant changes are demonstrated by bold letters. n.a.: not applicable.





Figure 2 Immunohistochemical stainings of tight junction-related proteins in esophageal mucosa. Occludin, Claudin-1, -2 and ZO-1,-2 are displayed by brown or red staining, respectively. Panels illustrate representative staining for controls and samples obtained from patients with NERD. Immunohistochemical staining was observed in the esophageal squamous epithelium mainly at the basal and suprabasal zone. Claudin-1/2 and ZO-1 showed partly a membranous staining. (Zeiss Axioskop 50; camera: Nikon coolpix 990).

not aimed to analyze the subcellular distribution pattern of the molecules in esophageal mucosa on the subcellular level. The presence of appropriate negative and positive control stainings in other tissues, and

the good concordance between expression data on transcript and protein level in general provide further indirect evidence for the specificity of immunohistochemical stainings.



Based on the descriptive study design, it remains open whether the altered gene expression levels of Claudin-1 and -2 contribute to GERD pathophysiology or merely are markers for the existing disease. Furthermore it is notable that the majority of patients received GERD

medications (PPI, H2RA) in the past before entering study. Even a stop of at least 2 weeks was mandatory to enter the study, we can not exclude that the effects of long-term therapy in the past or the changes induced by the 2-week stop of medication (e.g. acid rebound) [64]

Table 5 Correlation between GERD-specific histopathological alterations and gene expression level of tight junction-related genes (transcript level)

Panel A: All samples	Occludin	Claudin-1	Claudin-2	ZO-1	ZO-2
Activity	n.s.	$r = 0.23$ $P = 0.07$	n.s.	n.s.	n.s.
Chronicity	n.s.	n.s.	n.s.	n.s.	n.s.
Basal cell hyperplasia	n.s.	$r = 0.19$ $P = 0.05$	$r = 0.21$ $P = 0.04$	$r = 0.22$ $P = 0.03$	n.s.
Elongation of papilla	n.s.	n.s.	n.s.	n.s.	n.s.
Dilated intercellular space	n.s.	n.s.	n.s.	n.s.	n.s.
Panel B: Basal cell hyperplasia	Occludin	Claudin-1	Claudin-2	ZO-1	ZO-2
Controls	$r = 0.47$ $P = 0.02$	n.s.	n.s.	$r = 0.36$ $P = 0.08$	$r = 0.42$ $P = 0.04$
NERD	$r = 0.36$ $P = 0.03$	n.s.	n.s.	n.s.	n.s.
ERD	n.s.	n.s.	n.s.	n.s.	n.s.
GERD (ERD + NERD)	n.s.	n.s.	n.s.	n.s.	n.s.

Panel A: The histopathological scores (Table 3) were correlated with gene expression levels (transcript levels, Table 4) for each gene individually in the combined study cohort ($n = 110$). Data (r , and P -values) represent potential correlations between these parameters (n.s. = not significant). Panel B: Since basal cell hyperplasia demonstrated significant correlations in global analysis (Panel A), this parameter was further analyzed by correlating expression values for all five genes with basal cell hyperplasia within each group and for patients with GERD individually as identified in table.

could have affect the expression of the five genes studied. Another limitation is the assessment of protein expression by an immunohistochemical score that can be done semiquantitatively at best. Besides this methodological aspect, posttranscriptional regulatory mechanisms can lead to different findings between gene expression analysis performed on transcript and protein levels. But as mentioned above, overall we observed a good concordance between both levels even not all significant findings were confirmed by both methodologies. Since we studied five selected components of tight junction complexes in GERD only, general conclusions can not be made. Assessment of other tight junction related molecules (e.g. Claudins, JAMs, Tricellulin) [44,46,65] in regard to GERD needs to be performed.

Conclusions

In summary, this study demonstrates a partial upregulation of tight junction-related components, in particular Claudin-1, in relation to GERD. Since identified molecular changes do not correlate with histomorphological alterations in general, a major role of Claudin-1 as of the other four tight junction-related proteins in the pathogenesis of GERD can not be concluded from our study.

Abbreviations

BE: Barrett's esophagus; ERD: Erosive reflux disease; NERD: Nonerosive reflux disease; GEJ: Gastroesophageal junction; GERD: Gastroesophageal reflux disease; H2RA: Histamine-receptor antagonist; H. pylori: Helicobacter pylori; ICs: Intercellular spaces; INR: International normalized ratio; iNOS: Inducible nitro oxygen synthetase; JAM: Junctional adhesion molecule; NFkB: Nuclear factor kappa B; PAR-2: Protease activated receptor-2; PPI: Proton pump inhibitor; RDQ: Reflux disease questionnaire; ROS: Reactive oxygen species; RT-PCR: Reverse transcription polymerase chain reaction; ZO: Zona occludens.

Competing interests

The authors declare that they have no competing interest concerning the content of this article.

Authors' contributions

KM, PM and TW designed the study. KM, LCF enrolled the majority of patients. AK provided clinical data. TW coordinated and performed laboratory work. DK and AR provided histopathological and immunohistochemical data. TW and SK performed statistical analysis. The manuscript was drafted by TW, AK, DK, and reviewed for important intellectual content by KM and PM. All authors read and approved the final manuscript.

Acknowledgements

We thank the endoscopy team for their technical assistance and Ursula Stolz, Simone Philipsen and Nadine Schöler (all from the Division of Gastroenterology) and Nadine Wiest, Claudia Miethke and Carola Kügler (Institute of Pathology) for their excellent work in this study.

Author details

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Leipziger Str. 44, Magdeburg 39120, Germany. ²current address: Department of Gastroenterology, Hepatology, and Infectious Diseases Marienhospital, Bottrop 46236, Germany. ³Institute of Pathology, Otto-von-Guericke University, Leipziger Str. 44, Magdeburg D-39120, Germany. ⁴Institute of Biometrics and Medical Informatics, Otto-von-Guericke University, Leipziger Str. 44, Magdeburg D-39120, Germany.

Received: 11 June 2012 Accepted: 19 September 2012

Published: 20 September 2012

References

- Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. *Gastroenterology* 1997, **112**:1448–1456.
- Kang JY: Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2004, **20**:705–717.
- Malfertheiner P, Hallerback B: Clinical manifestations and complications of gastroesophageal reflux disease (GERD). *Int J Clin Pract* 2005, **59**:346–355.
- Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group: The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006, **101**:1900–1920.
- Genta RM, Spechler SJ, Kielhorn AF: The Los Angeles and Savary-Miller systems for grading esophagitis: utilization and correlation with histology. *Dis Esophagus* 2011, **24**:10–17.
- Winter JW, Heading RC: The nonerosive reflux disease-gastroesophageal reflux disease controversy. *Curr Opin Gastroenterol* 2008, **24**:509–515.
- Fry LC, Mönkemüller K, Malfertheiner P: Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions—a debate: con. *Curr Treat Options Gastroenterol*. 2007, **10**:305–311.
- Ismail-Beigi F, Horton PF, Pope CE 2nd: Histological consequences of gastroesophageal reflux in man. *Gastroenterology* 1970, **58**:163–174.
- Vieth M, Peitz U, Labenz J, Kulig M, Naucleer E, Jaspersen D, Meyer-Sabellek W, Willich S, Lind T, Malfertheiner P, Stolte M: What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa? *Dig Dis* 2004, **22**:196–201.
- Neumann H, Mönkemüller K, Fry LC, Dombrowski F, Kuester D, Beyer M, Malfertheiner P: Intercellular space volume is mainly increased in the basal layer of esophageal squamous epithelium in patients with GERD. *Dig Dis Sci* 2011, **56**:1404–1411.
- Glickman JN, Spechler SJ, Souza RF, Lunsford T, Lee E, Odze RD: Multilayered epithelium in mucosal biopsy specimens from the gastroesophageal junction region is a histologic marker of gastroesophageal reflux disease. *Am J Surg Pathol* 2009, **33**:818–825.
- Orlando LA, Orlando RC: Dilated intercellular spaces as a marker of GERD. *Curr Gastroenterol Rep* 2009, **11**:190–194.
- Tobey NA, Carson JL, Alkiek RA, Orlando RC: Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. *Gastroenterology* 1996, **111**:1200–1205.
- Calabrese C, Fabbri A, Bortolotti M, Cenacchi G, Areni A, Scialpi C, Miglioli M, Di Febo G: Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. *Aliment Pharmacol Ther* 2003, **18**:525–532.
- Orlando RC: Pathophysiology of gastroesophageal reflux disease. *J Clin Gastroenterol* 2008, **42**:584–588.
- Bredenoord AJ: Mechanisms of reflux perception in gastroesophageal reflux disease: a review. *Am J Gastroenterol* 2012, **107**:8–15.
- Long JD, Orlando RC: Nonerosive reflux disease: a pathophysiologic perspective. *Curr Gastroenterol Rep* 2008, **10**:200–207.
- Farré R, De Vos R, Geboes K, Verbeke K, Vanden Berghe P, Depoortere I, Blondeau K, Tack J, Sifrim D: Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. *Gut* 2007, **56**:1191–1197.
- Jovov B, Que J, Tobey NA, Djukic Z, Hogan BL, Orlando RC: Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease. *Am J Gastroenterol* 2011, **106**:1039–1047.
- Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ: Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. *Gastroenterology* 2009, **137**:1776–1784.
- Niessen CM: Tight junctions/adherens junctions: basic structure and function. *J Invest Dermatol* 2007, **127**:2525–2532.
- Garrod D, Chidgey M: Desmosome structure, composition and function. *Biochim Biophys Acta* 2008, **1778**:572–587.

23. Thomason HA, Scothern A, McHarg S, Garrod DR: **Desmosomes: adhesive strength and signalling in health and disease.** *Biochem J* 2010, **429**:419–433.
24. Yu QH, Yang Q: **Diversity of tight junctions (TJs) between gastrointestinal epithelial cells and their function in maintaining the mucosal barrier.** *Cell Biol Int* 2009, **33**:78–82.
25. Souza RF, Freschi G, Taddei A, Ringressi MN, Bechi P, Castiglione F, Rossi Degl'Innocenti D, Triadafilopoulos G, Wang JS, Chang AC, Barr H, Bajpai M, Das KM, Schneider PM, Krishnadh KK, Malhotra U, Lynch JP: **Barrett's esophagus: genetic and cell changes.** *Ann N Y Acad Sci* 2011, **1232**:18–35.
26. Jovov B, Van Itallie CM, Shaheen NJ, Carson JL, Gambling TM, Anderson JM, Orlando RC: **Claudin-18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance.** *Am J Physiol Gastrointest Liver Physiol* 2007, **293**:G1106–G1113.
27. Mullin JM, Valenzano MC, Trembeth S, Allegretti PD, Verrecchio JJ, Schmidt JD, Jain V, Meddings JB, Mercogliano G, Thornton JJ: **Transepithelial leak in Barrett's esophagus.** *Dig Dis Sci* 2006, **51**:2326–2336.
28. Montgomery E, Mamelak AJ, Gibson M, Maitra A, Sheikh S, Amr SS, Yang S, Brock M, Forastiere A, Zhang S, Murphy KM, Berg KD: **Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.** *Appl Immunohistochem Mol Morphol* 2006, **14**:24–30.
29. Fang D, Das KM, Cao W, Malhotra U, Triadafilopoulos G, Najarian RM, Hardie LJ, Lightdale CJ, Beales IL, Felix VN, Schneider PM, Bellizzi AM: **Barrett's esophagus: progression to adenocarcinoma and markers.** *Ann N Y Acad Sci* 2011, **1232**:210–229.
30. Weimann A, Rieger A, Zimmermann M, Gross M, Hoffmann P, Slevogt H, Morawietz L: **Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.** *Virchows Arch* 2010, **457**:537–545.
31. Oguro M, Koike M, Ueno T, Asaoka D, Mori H, Nagahara A, Uchiyama Y, Watanabe S: **Dissociation and dispersion of claudin-3 from the tight junction could be one of the most sensitive indicators of reflux esophagitis in a rat model of the disease.** *J Gastroenterol* 2011, **46**:629–638.
32. Miwa H, Koseki J, Oshima T, Kondo T, Tomita T, Watari J, Matsumoto T, Hattori T, Kubota K, Iizuka S: **Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa.** *J Gastroenterol* 2010, **45**:478–487.
33. Oshima T, Koseki J, Chen X, Matsumoto T, Miwa H: **Acid modulates the squamous epithelial barrier function by modulating the localization of claudins in the superficial layers.** *Lab Invest* 2012, **92**:22–31.
34. Mönkemüller K, Wex T, Kuester D, Fry LC, Peitz U, Beyer M, Roessner A, Malfertheiner P: **Interleukin-1beta and interleukin-8 expression correlate with the histomorphological changes in esophageal mucosa of patients with erosive and non-erosive reflux disease.** *Digestion* 2009, **79**:186–195.
35. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: **Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification.** *Gut* 1999, **45**:172–180.
36. Kandulski A, Wex T, Mönkemüller K, Kuester D, Fry LC, Roessner A, Malfertheiner P: **Protease-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease.** *Am J Gastroenterol* 2010, **105**:1934–1943.
37. Wex T, Mönkemüller K, Kuester D, Fry L, Kandulski A, Malfertheiner P: **Zonulin is not increased in the cardiac and esophageal mucosa of patients with gastroesophageal reflux disease.** *Peptides* 2009, **30**:1082–1087.
38. Wex T, Mönkemüller K, Kuester D, Weise S, Kropf S, Fry LC, Stahr A, Völkel S, Roessner A, Malfertheiner P: **Gastroesophageal reflux disease does not lead to changes in the secretory leukocyte protease inhibitor expression in esophageal mucosa.** *Eur J Gastroenterol Hepatol* 2009, **21**:150–158.
39. Wex T, Mönkemüller K, Stahr A, Kuester D, Fry LC, Völkel S, Kandulski A, Roessner A, Malfertheiner P: **Gastroesophageal reflux disease is associated with an upregulation of desmosomal components in esophageal mucosa.** *Histopathology* 2012, **60**:405–415.
40. Wex T, Treiber G, Lendeckel U, Malfertheiner P: **A two-step method for the extraction of high-quality RNA from endoscopic biopsies.** *Clin Chem Lab Med* 2003, **41**:1033–1037.
41. Schmittgen TD, Livak KJ: **Analyzing real-time PCR data by the comparative C(T) method.** *Nat Protoc* 2008, **3**:1101–1108.
42. Remmele W, Stegner HE: **Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue.** *Pathologe* 1987, **8**:138–140.
43. Balda MS, Matter K: **Tight junctions and the regulation of gene expression.** *Biochim Biophys Acta* 2009, **1788**:761–767.
44. Ichikawa-Tomikawa N, Sugimoto K, Satohisa S, Nishiura K, Chiba H: **Possible involvement of tight junctions, extracellular matrix and nuclear receptors in epithelial differentiation.** *J Biomed Biotechnol* 2011, **2011**:253048.
45. Cummins PM: **Occludin: one protein, many forms.** *Mol Cell Biol* 2012, **32**:242–250.
46. Escudero-Esparza A, Jiang WG, Martin TA: **The Claudin family and its role in cancer and metastasis.** *Front Biosci* 2011, **16**:1069–1083.
47. Rosenthal R, Milatz S, Oelrich B, Schulzke JD, Amasheh S, Günzel D, Fromm M: **Claudin-2, a component of the tight junction, forms a paracellular water channel.** *J Cell Sci* 2010, **123**:1913–1921.
48. Fanning AS, Anderson JM: **Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of cellular junctions.** *Ann N Y Acad Sci* 2009, **1165**:113–120.
49. Gonzalez-Mariscal L, Quiros M, Diaz-Coranguel M: **ZO proteins and Redox dependent processes.** *Antioxid Redox Signal* 2011, **15**:1235–1253.
50. Kandulski A, Malfertheiner P: **Gastroesophageal reflux disease-from reflux episodes to mucosal inflammation.** *Nat Rev Gastroenterol Hepatol* 2011, **9**:15–22.
51. Rieder F, Biancani P, Harnett K, Yerian L, Falk GW: **Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.** *Am J Physiol Gastrointest Liver Physiol* 2010, **298**:G571–G581.
52. Farré R, van Malenstein H, De Vos R, Geboes K, Depoortere I, Vanden Bergh P, Fornari F, Blondeau K, Mertens V, Tack J, Sifrim D: **Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces.** *Gut* 2008, **57**:1366–1374.
53. Tobey NA, Hosseini SS, Argote CM, Dobrucali AM, Awayda MS, Orlando RC: **Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium.** *Am J Gastroenterol* 2004, **99**:13–22.
54. Chen X, Oshima T, Tomita T, Fukui H, Watari J, Matsumoto T, Miwa H: **Acidic bile salts modulate the squamous epithelial barrier function by modulating tight junction proteins.** *Am J Physiol Gastrointest Liver Physiol* 2011, **301**:G203–G209.
55. Chen X, Oshima T, Shan J, Fukui H, Watari J, Miwa H: **Bile salts disrupt human esophageal squamous epithelial barrier function by modulating tight junction proteins.** *Am J Physiol Gastrointest Liver Physiol* 2012, **303**:G199–G208.
56. Suzuki T, Yoshinaga N, Tanabe S: **IL-6 regulates claudin-2 expression and tight junction permeability in intestinal epithelium.** *J Biol Chem* 2011, **286**:31263–31271.
57. Li FY, Li Y: **Interleukin-6, desmosome and tight junction protein expression levels in reflux esophagitis-affected mucosa.** *World J Gastroenterol* 2009, **15**:3621–3630.
58. Rieder F, Cheng L, Harnett KM, Chak A, Cooper GS, Isenberg G, Ray M, Katz JA, Catanzaro A, O'Shea R, Post AB, Wong R, Sivak MV, McCormick T, Phillips M, West GA, Willis JE, Biancani P, Fiocchi C: **Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities.** *Gastroenterology* 2007, **132**:154–165.
59. Kimura Y, Shiozaki H, Hirao M, Maeno Y, Doki Y, Inoue M, Monden T, Ando-Akatsuka Y, Furuse M, Tsukita S, Monden M: **Expression of occludin, tight-junction-associated protein, in human digestive tract.** *Am J Pathol* 1997, **151**:45–54.
60. Halász J, Holczbauer A, Páska C, Kovács M, Benyó G, Verebely T, Schaff Z, Kiss A: **Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma.** *Hum Pathol* 2006, **37**:555–561.
61. Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E, Moss SF: **Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation.** *Hum Pathol* 2005, **36**:886–892.
62. Asaoka D, Miwa H, Hirai S, Ohkawa A, Kurosawa A, Kawabe M, Hojo M, Nagahara A, Minoo T, Ohkura R, Ohkusa T, Sato N: **Altered localization and expression of tight-junction proteins in a rat model with chronic acid reflux esophagitis.** *J Gastroenterol* 2005, **40**:781–790.

63. Aijaz S, Balda MS, Matter K: **Tight junctions: molecular architecture and function.** *Int Rev Cytol* 2006, **248**:261–298.
64. Hunfeld NG, Geus WP, Kuipers EJ: **Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors.** *Aliment Pharmacol Ther* 2007, **25**:39–46.
65. Ikenouchi J, Furuse M, Furuse K, Sasaki H, Tsukita S, Tsukita S: **Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells.** *J Cell Biol* 2005, **171**:939–945.

doi:10.1186/1471-230X-12-128

Cite this article as: Mönkemüller *et al.*: Role of tight junction proteins in gastroesophageal reflux disease. *BMC Gastroenterology* 2012 **12**:128.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

